deltatrials
Recruiting OBSERVATIONAL NCT04917887

Long-Term Follow-up Protocol

A Prospective, Observational, Long-Term Follow-Up (LTFU) Study to Evaluate the Long-Term Safety of the Krystal Biotech, Inc. Gene Therapy Backbone Products Using HSV-1 Backbone

Sponsor: Krystal Biotech, Inc.

Conditions Dominant Dystrophic Epidermolysis Bullosa Dystrophic Epidermolysis Bullosa Recessive Dystrophic Epidermolysis Bullosa
Updated 3 times since 2021 Last updated: Jun 7, 2021 Started: May 25, 2021 Primary completion: May 25, 2028 Completion: May 25, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04917887, this observational or N/A phase trial focuses on Dominant Dystrophic Epidermolysis Bullosa and Dystrophic Epidermolysis Bullosa and remains actively recruiting participants. Sponsored by Krystal Biotech, Inc., it has been updated 3 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Sep 2024 — Present [monthly]

    Recruiting

  2. Jul 2024 — Sep 2024 [monthly]

    Recruiting

  3. Sep 2021 — Jul 2024 [monthly]

    Recruiting

    First recorded

May 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Krystal Biotech, Inc.
Data source: Krystal Biotech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations